investors Relations



BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Drug Discovery

BenevolentAI has a proven track-record of scientifically validated discoveries. The Benevolent Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA.

disease area
target id
chemistry & lead optimization
BEN2293 | atopic dermatitis
BEN8744 | ulcerative colitis
BEN9160 | amyotrophic lateral sclerosis
glioblastoma multiforme
inflammatory bowel diseases
atopic dermatitis
ulcerative colitis
amyotrophic lateral sclerosis
inflammatory bowel diseases
glioblastoma miltiforme
View Full Pipeline

Press Releases

BenevolentAI & Odyssey Combination

Presentations & Webcasts

Corporate Governance

Press Releases
& Events

all press releases→

Latest News

May 17, 2022

AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.

May 5, 2022


May 6, 2022

Join our SVP of Informatics and Data, Mark Davies, at the LSX World Congress for a panel on how AI, machine learning & big data are disrupting the drug discovery & development landscape for faster and more accurate lead identification.

May 22, 2022

Our CEO Joanna Shields joins the World Economic Forum’s Annual Meeting in Davos for two panels on ‘Unlocking the Power of Digital Health’ and the ‘Use of Responsible AI for Societal Gains’.